| Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach A Brekkan, R Lledo-Garcia, B Lacroix, S Jönsson, MO Karlsson, EL Plan Journal of Pharmacokinetics and Pharmacodynamics 51 (1), 65-75, 2024 | | 2024 |
| Therapeutic drug monitoring of vancomycin and meropenem: Illustration of the impact of inaccurate information in dose administration time M Swartling, T Tängdén, M Lipcsey, S Jönsson, EI Nielsen International Journal of Antimicrobial Agents 63 (1), 107032, 2024 | | 2024 |
| A model‐based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno‐oncology J Sánchez, C Claus, R Albrecht, BC Gaillard, J Marinho, C McIntyre, ... CPT: Pharmacometrics & Systems Pharmacology 12 (11), 1804-1818, 2023 | 1 | 2023 |
| A multistate modeling and simulation framework to learn dose–response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer H Liu, AM Milenković‐Grišić, SM Krishnan, S Jönsson, LE Friberg, ... CPT: Pharmacometrics & Systems Pharmacology 12 (11), 1738-1750, 2023 | 4 | 2023 |
| Relationship between factor VIII levels and bleeding for rFVIII‐SingleChain in severe hemophilia A: A repeated time‐to‐event analysis LH Bukkems, S Jönsson, MH Cnossen, MO Karlsson, RAA Mathôt, ... CPT: Pharmacometrics & Systems Pharmacology 12 (5), 706-718, 2023 | 1 | 2023 |
| Association between sports participation, factor VIII levels and bleeding in hemophilia A LH Bukkems, O Versloot, MH Cnossen, S Jönsson, MO Karlsson, ... Thrombosis and haemostasis 123 (03), 317-325, 2023 | 6 | 2023 |
| A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study JJ Swen, CH van der Wouden, LEN Manson, H Abdullah-Koolmees, ... The Lancet 401 (10374), 347-356, 2023 | 183 | 2023 |
| Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis A Moein, T Lu, S Jönsson, J Ribbing, N Kassir, W Zhang, G Sperinde, ... CPT: Pharmacometrics & Systems Pharmacology 11 (9), 1244-1255, 2022 | 4 | 2022 |
| Model-based characterization of the bidirectional interaction between pharmacokinetics and tumor growth dynamics in patients with metastatic Merkel cell carcinoma treated with … AM Grisic, W Xiong, L Tanneau, S Jönsson, LE Friberg, MO Karlsson, ... Clinical Cancer Research 28 (7), 1363-1371, 2022 | 2 | 2022 |
| Population pharmacokinetics of cefotaxime in intensive care patients M Swartling, AK Smekal, M Furebring, M Lipcsey, S Jönsson, EI Nielsen European journal of clinical pharmacology, 1-8, 2021 | 7 | 2021 |
| Detecting placebo and drug effects on Parkinson's disease symptoms by longitudinal item‐score models C Chen, S Jönsson, S Yang, EL Plan, MO Karlsson CPT: Pharmacometrics & Systems Pharmacology 10 (4), 309-317, 2021 | 7 | 2021 |
| Pharmacometrics-based considerations for the design of a pharmacogenomic clinical trial assessing irinotecan safety IK Minichmayr, MO Karlsson, S Jönsson Pharmaceutical research 38, 593-605, 2021 | 4 | 2021 |
| Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study CH van der Wouden, S Böhringer, E Cecchin, KC Cheung, ... Pharmacogenetics and Genomics 30 (6), 131-144, 2020 | 35 | 2020 |
| A novel, enriched population pharmacokinetic model for recombinant factor VIII-Fc fusion protein concentrate in hemophilia A patients LH Bukkems, JM Heijdra, M Mathias, PW Collins, CRM Hay, RC Tait, ... Thrombosis and haemostasis 120 (05), 747-757, 2020 | 11 | 2020 |
| Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients JA Abrantes, A Solms, D Garmann, EI Nielsen, S Jönsson, MO Karlsson haematologica 105 (5), 1443, 2020 | 24 | 2020 |
| Body mass index best predicts recovery of recombinant factor VIII in underweight to obese patients with severe haemophilia A A Tiede, AR Cid, G Goldmann, V Jiménez-Yuste, M Pluta, T Lissitchkov, ... Thrombosis and Haemostasis 120 (02), 277-288, 2020 | 9 | 2020 |
| Handling underlying discrete variables with bivariate mixed hidden Markov models in NONMEM A Brekkan, S Jönsson, MO Karlsson, EL Plan Journal of Pharmacokinetics and Pharmacodynamics 46, 591-604, 2019 | 7 | 2019 |
| Bayesian forecasting utilizing bleeding information to support dose individualization of factor VIII JA Abrantes, A Solms, D Garmann, EI Nielsen, S Jönsson, MO Karlsson CPT: Pharmacometrics & Systems Pharmacology 8 (12), 894-903, 2019 | 12 | 2019 |
| Handling interoccasion variability in model‐based dose individualization using therapeutic drug monitoring data JA Abrantes, S Jönsson, MO Karlsson, EI Nielsen British journal of clinical pharmacology, 2019 | 56 | 2019 |
| Model‐based evaluation of low‐dose factor VIII prophylaxis in haemophilia A A Brekkan, J Degerman, S Jönsson Haemophilia 25 (3), 408-415, 2019 | 10 | 2019 |
Mats KarlssonUppsala UniversityVerified email at farmaci.uu.se
